The logo for AstraZeneca is seen outside its North America headquarters in Wilmington, Delaware, U.S., March 22, 2021. REUTERS FILE PHOTO
AstraZeneca said on Monday its cancer drugs Lynparza, developed with Merck & Co and Enhertu, developed with Japan’s Daiichi Sankyo, were recommended for the treatment of some high-risk breast cancers in the European Union.
RELATED STORIES
Free breast cancer information source launched
New radiation treatment shows hope for early breast cancer patients